ELISpot and FluoroSpot Assay Market Size, Share & Trends Analysis Report By Product (Prospective, Retrospective), By Application (Oncology, Neurology, Cardiology), By End-use, By Region,- Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2025-2034

ELISpot And Fluorospot Assay Market Size and Growth

The ELISpot and fluorospot assay market size was exhibited at USD 311.32 million in 2024 and is projected to hit around USD 578.93 million by 2034, growing at a CAGR of 6.4% during the forecast period 2025 to 2034.

ELISpot and FluoroSpot Assay Market Size 2024 To 2034

ELISpot and Fluorospot Assay Market Key Takeaways:

  • Assay kits dominated the market and accounted for a share of 49.6% in 2024.
  • The demand for analyzers is expected to grow lucratively over the forecast period.
  • Diagnostic applications led the market with a revenue share of 66.1% in 2024.
  • Research applications are expected to register significant growth over the forecast period
  • Hospitals and clinical labs held the largest revenue share of 47.0% in 2024.
  • Biopharmaceutical companies are projected to grow at the fastest CAGR of 6.6% over the forecast period.
  • North America ELISpot and fluorospot assay market dominated the global market with a revenue share of 36.0% in 2024.

U.S. ELISpot and Fluorospot Assay Market Size and Growth 2025 to 2034

The U.S. ELISpot and fluorospot assay market size is evaluated at USD 84.1 million in 2024 and is projected to be worth around USD 156.3 million by 2034, growing at a CAGR of 5.79% from 2025 to 2034.

U.S. ELISpot and Fluorospot Assay Market Size 2024 To 2034

North America ELISpot and fluorospot assay market dominated the global market with a revenue share of 36.0% in 2024, driven by established healthcare infrastructure, robust R&D activities, and widespread adoption of advanced diagnostics. The region’s high testing volume, with over 20 million individuals tested annually for TB in the U.S., and the preference for IGRA tests such as the T-SPOT.TB, are key factors contributing to the segment’s growth and increasing acceptance of ELISpot technology.

Stacked Graph 0

U.S. ELISpot and Fluorospot Assay Market Trends

The ELISpot and fluorospot assay market in the U.S. dominated the North America market with a revenue share of 83.0% in 2024, fueled by the high funding for biomedical research, high presence of various research institutions and strong presence of pharmaceutical and biotechnology companies investing in vaccine development, drug discovery, and clinical trials. U.S. accounts for the largest number of clinical trials performed globally. According to the WHO ICTRP data, 168,520 clinical trials were performed in the U.S. from 1999 to 2022. Such focus on R&D is anticipated to drive the demand for ELISpot and Fluorospot assays in the country.

Europe ELISpot and Fluorospot Assay Market Trends

Europe ELISpot and fluorospot assay market held substantial market share in 2024, driven by factors such as the growing burden of chronic and infectious diseases, increasing emphasis on early disease diagnosis, and high research focus. Europe has a robust research infrastructure and a strong commitment to scientific progress. These factors foster the development and application of ELISpot and Fluorospot assays in various research areas, such as vaccine development and immunology.

The ELISpot and fluorospot assay market in UK is expected to grow in the forecast period due to the rising prevalence of chronic diseases, increased research in immunology, and greater awareness of early diagnostic practices. With approximately 18% of the population aged over 65, there is a mounting demand for advanced diagnostic technologies to effectively monitor immune responses and address elevated healthcare needs.

Asia Pacific ELISpot and Fluorospot Assay Market Trends

Asia Pacific ELISpot and fluorospot assay market is expected to register the fastest CAGR of 7.2% in the forecast period. This can be attributed to the increasing prevalence of various diseases such as diabetes, cancer, tuberculosis, and hepatitis B. For instance, according to the WHO data, around 2.3 million people in Southeast Asia region are diagnosed with cancer each year, and it causes around 1.4 million mortalities each year. The rising prevalence has increased the need for the development of advanced treatments, leading to R&D activities in the region and thereby driving its growth.

The ELISpot and fluorospot assay market in China is projected to grow at the fastest CAGR of 9.4% over the forecast period, propelled by rapid advancements in biotechnology and a rising incidence of chronic diseases. With a population surpassing 1.4 billion, the demand for effective diagnostic tools is critical. Furthermore, government initiatives to enhance healthcare infrastructure and fund biomedical research further facilitate the growth of these assays in addressing public health challenges.

Report Scope of ELISpot and Fluorospot Assay Market

Report Coverage Details
Market Size in 2025 USD 331.24 Million
Market Size by 2034 USD 578.93 Million
Growth Rate From 2025 to 2034 CAGR of 6.4%
Base Year 2024
Forecast Period 2025-2034
Segments Covered Product, Application, End-use, Region
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Regional scope North America; Europe; Asia Pacific; Latin America; MEA
Key Companies Profiled BD; U-CyTech; Cellular Technology Limited; Mabtech; Abcam Limited; Autoimmun Diagnostika GmbH; Lophius Biosciences GmbH; Bio-Connect B.V.; Oxford Immunotec; Bio-Techne Corporation

ELISpot and Fluorospot Assay Market By Product Insights

Assay kits dominated the market and accounted for a share of 49.6% in 2024. The enzyme-linked immunospot (ELISpot) assay is a highly sensitive and effective immunoassay for monitoring immune responses in vitro. By allowing ex vivo measurements of antibody-secreting cells or cytokines at the single-cell level, these kits employ sandwich immuno-enzyme technology to accurately detect and quantify secretory products. Applicable across transplantation, vaccine development, autoimmune diseases, and infections, ELISpot kits are invaluable for research and clinical applications.

The demand for analyzers is expected to grow lucratively over the forecast period, owing to the rising availability of advanced models and increasing demand for high-throughput analysis. In research areas such as immunology and drug discovery, the need for efficient processing of large sample volumes drives the demand for high-throughput analyzers. CTL’s ImmunoSpot Analyzers are market leaders, offering multifunctionality for various immune monitoring tests to meet diverse needs and budgets.

ELISpot and Fluorospot Assay Market By Application Insights

Diagnostic applications led the market with a revenue share of 66.1% in 2024. ELISpot and Fluorospot assays provide high sensitivity and specificity for detecting immune responses to pathogens and antigens, enabling accurate diagnosis of infectious diseases such as tuberculosis, HIV, and viral infections. Their utility in autoimmune disease diagnosis and growth in immunology and oncology are expected to further enhance their diagnostic applications.

Research applications are expected to register significant growth over the forecast period due to the capability of these assays to identify potential drug candidates that modulate immune responses. The ELISPOT assay serves as a key immune monitoring tool, applicable in evaluating responses to infections, transplant antigens, tumor antigens, and autoantigens. Its utility in assessing drug impacts on immune cell activation and cytokine production is expected to further drive demand.

ELISpot and Fluorospot Assay Market By End-use Insights

Hospitals and clinical labs held the largest revenue share of 47.0% in 2024. Hospitals and clinical labs serve as direct contact points for patients suffering from various diseases, increasing the pressure on these healthcare systems for rapid diagnosis. ELISpot and fluorospot assays, emerging as important tools for disease diagnosis, are thus anticipated to witness growth in the hospitals and clinical labs segment.

Pie Graph 0

Biopharmaceutical companies are projected to grow at the fastest CAGR of 6.6% over the forecast period. Biopharmaceutical companies are driven to use ELISpot and Fluorospot assays due to their high quantitative accuracy, ability to measure a wide range of immune responses, and versatility in evaluating T-cell functions, B cells, and innate immune cells. Their proven clinical relevance, particularly in predicting therapeutic outcomes in cancer vaccine trials, enhances their appeal in clinical applications.

Some of the prominent players in the ELISpot and fluorospot assay market include:

ELISpot and Fluorospot Assay Market Recent Developments

  • In September 2023, Virax Biolabs Group Limited launched a program offering researchers early access to its SARS-Cov-2 ViraxImmune T-cell-based test. This test assesses the activation of memory T-cells specifically to the SARS-Cov-2 by combining the company’s precoated ELISpot assay to a peptide pool covering a specific part of the virus.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the ELISpot and fluorospot assay market

By Product

  • Assay Kits
  • Analyzers
  • Ancillary Products

By Application

  • Research Applications
  • Diagnostics Applications

By End-use

  • Hospital and Clinical Labs
  • Academic and Research Institutes
  • Biopharmaceutical Company

By Regional

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa (MEA)

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope

1.2. Segment Definitions

1.2.1. Product

1.2.2. Application

1.2.3. End Use

1.3. Estimates and Forecast Timeline

1.4. Research Methodology

1.5. Information Procurement

1.5.1. Purchased Database

1.5.2. Internal Database

1.5.3. Secondary Sources

1.5.4. Primary Research

1.6. Information Analysis

1.6.1. Data Analysis Models

1.7. Market Formulation & Data Visualization

1.8. Model Details

1.8.1. Commodity Flow Analysis

1.9. List of Secondary Sources

1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot

2.2. Segment Snapshot

2.3. Competitive Landscape Snapshot

Chapter 3. ELISpot and Fluorospot Assay Market Variables, Trends, & Scope

3.1. Market Lineage Outlook

3.2. Market Dynamics

3.2.1. Market Driver Analysis

3.2.2. Market Restraint Analysis

3.3. Business Environment Analysis

3.3.1. Industry Analysis - Porter’s Five Forces Analysis

3.3.1.1. Supplier Power

3.3.1.2. Buyer Power

3.3.1.3. Substitution Threat

3.3.1.4. Threat of New Entrants

3.3.1.5. Competitive Rivalry

3.3.2. PESTLE Analysis

Chapter 4. ELISpot and Fluorospot Assay Market: Product Business Analysis

4.1. Product Market Share, 2024 & 2034

4.2. Product Segment Dashboard

4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)

4.4. Assay Kits

4.4.1. Assay Kits Market, 2021 - 2034 (USD Million)

4.5. Analyzers

4.5.1. Analyzers Market, 2021 - 2034 (USD Million)

4.6. Ancillary Products

4.6.1. Ancillary Products Market, 2021 - 2034 (USD Million)

Chapter 5. ELISpot and Fluorospot Assay Market: Application Business Analysis

5.1. Application Market Share, 2024 & 2034

5.2. Application Segment Dashboard

5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)

5.4. Research Applications

5.4.1. Research Applications Market, 2021 - 2034 (USD Million)

5.5. Diagnostics Applications

5.5.1. Diagnostics Applications Market, 2021 - 2034 (USD Million)

Chapter 6. ELISpot and Fluorospot Assay Market: End Use Business Analysis

6.1. End Use Market Share, 2024 & 2034

6.2. End Use Segment Dashboard

6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)

6.4. Hospital and Clinical Labs

6.4.1. Hospital and Clinical Labs Market, 2021 - 2034 (USD Million)

6.5. Academic and Research Institutes

6.5.1. Academic and Research Institutes Market, 2021 - 2034 (USD Million)

6.6. Biopharmaceutical Company

6.6.1. Biopharmaceutical Company Market, 2021 - 2034 (USD Million)

Chapter 7. ELISpot and Fluorospot Assay Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2024 & 2034

7.2. Regional Market Dashboard

7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:

7.4. North America

7.4.1. North America ELISpot and Fluorospot Assay Market Estimates And Forecasts, By Country, 2021 - 2034 (USD Million)

7.4.2. U.S.

7.4.2.1. Key Country Dynamics

7.4.2.2. Regulatory Framework

7.4.2.3. Competitive Insights

7.4.2.4. U.S. ELISpot and Fluorospot Assay Market Estimates And Forecasts, 2021 - 2034 (USD Million)

7.4.3. Canada

7.4.3.1. Key Country Dynamics

7.4.3.2. Regulatory Framework

7.4.3.3. Competitive Insights

7.4.3.4. Canada ELISpot and Fluorospot Assay Market Estimates And Forecasts, 2021 - 2034 (USD Million)

7.4.4. Mexico

7.4.4.1. Key Country Dynamics

7.4.4.2. Regulatory Framework

7.4.4.3. Competitive Insights

7.4.4.4. Mexico ELISpot and Fluorospot Assay Market Estimates And Forecasts, 2021 - 2034 (USD Million)

7.5. Europe

7.5.1. Europe ELISpot and Fluorospot Assay Market Estimates And Forecasts, By Country, 2021 - 2034 (USD Million)

7.5.2. UK

7.5.2.1. Key Country Dynamics

7.5.2.2. Regulatory Framework

7.5.2.3. Competitive Insights

7.5.2.4. UK ELISpot and Fluorospot Assay Market Estimates And Forecasts, 2021 - 2034 (USD Million)

7.5.3. Germany

7.5.3.1. Key Country Dynamics

7.5.3.2. Regulatory Framework

7.5.3.3. Competitive Insights

7.5.3.4. Germany ELISpot and Fluorospot Assay Market Estimates And Forecasts, 2021 - 2034 (USD Million)

7.5.4. France

7.5.4.1. Key Country Dynamics

7.5.4.2. Regulatory Framework

7.5.4.3. Competitive Insights

7.5.4.4. France ELISpot and Fluorospot Assay Market Estimates And Forecasts, 2021 - 2034 (USD Million)

7.5.5. Italy

7.5.5.1. Key Country Dynamics

7.5.5.2. Regulatory Framework

7.5.5.3. Competitive Insights

7.5.5.4. Italy ELISpot and Fluorospot Assay Market Estimates And Forecasts, 2021 - 2034 (USD Million)

7.5.6. Spain

7.5.6.1. Key Country Dynamics

7.5.6.2. Regulatory Framework

7.5.6.3. Competitive Insights

7.5.6.4. Spain ELISpot and Fluorospot Assay Market Estimates And Forecasts, 2021 - 2034 (USD Million)

7.5.7. Norway

7.5.7.1. Key Country Dynamics

7.5.7.2. Regulatory Framework

7.5.7.3. Competitive Insights

7.5.7.4. Norway ELISpot and Fluorospot Assay Market Estimates And Forecasts, 2021 - 2034 (USD Million)

7.5.8. Denmark

7.5.8.1. Key Country Dynamics

7.5.8.2. Regulatory Framework

7.5.8.3. Competitive Insights

7.5.8.4. Denmark ELISpot and Fluorospot Assay Market Estimates And Forecasts, 2021 - 2034 (USD Million)

7.5.9. Sweden

7.5.9.1. Key Country Dynamics

7.5.9.2. Regulatory Framework

7.5.9.3. Competitive Insights

7.5.9.4. Sweden ELISpot and Fluorospot Assay Market Estimates And Forecasts, 2021 - 2034 (USD Million)

7.6. Asia Pacific

7.6.1. Asia Pacific ELISpot and Fluorospot Assay Market Estimates And Forecasts, By Country, 2021 - 2034 (USD Million)

7.6.2. Japan

7.6.2.1. Key Country Dynamics

7.6.2.2. Regulatory Framework

7.6.2.3. Competitive Insights

7.6.2.4. Japan ELISpot and Fluorospot Assay Market Estimates And Forecasts, 2021 - 2034 (USD Million)

7.6.3. China

7.6.3.1. Key Country Dynamics

7.6.3.2. Regulatory Framework

7.6.3.3. Competitive Insights

7.6.3.4. China ELISpot and Fluorospot Assay Market Estimates And Forecasts, 2021 - 2034 (USD Million)

7.6.4. India

7.6.4.1. Key Country Dynamics

7.6.4.2. Regulatory Framework

7.6.4.3. Competitive Insights

7.6.4.4. India ELISpot and Fluorospot Assay Market Estimates And Forecasts, 2021 - 2034 (USD Million)

7.6.5. South Korea

7.6.5.1. Key Country Dynamics

7.6.5.2. Regulatory Framework

7.6.5.3. Competitive Insights

7.6.5.4. South Korea ELISpot and Fluorospot Assay Market Estimates And Forecasts, 2021 - 2034 (USD Million)

7.6.6. Australia

7.6.6.1. Key Country Dynamics

7.6.6.2. Regulatory Framework

7.6.6.3. Competitive Insights

7.6.6.4. Australia ELISpot and Fluorospot Assay Market Estimates And Forecasts, 2021 - 2034 (USD Million)

7.6.7. Thailand

7.6.7.1. Key Country Dynamics

7.6.7.2. Regulatory Framework

7.6.7.3. Competitive Insights

7.6.7.4. Thailand ELISpot and Fluorospot Assay Market Estimates And Forecasts, 2021 - 2034 (USD Million)

7.7. Latin America

7.7.1. Latin America ELISpot and Fluorospot Assay Market Estimates And Forecasts, By Country, 2021 - 2034 (USD Million)

7.7.2. Brazil

7.7.2.1. Key Country Dynamics

7.7.2.2. Regulatory Framework

7.7.2.3. Competitive Insights

7.7.2.4. Brazil ELISpot and Fluorospot Assay Market Estimates And Forecasts, 2021 - 2034 (USD Million)

7.7.3. Argentina

7.7.3.1. Key Country Dynamics

7.7.3.2. Regulatory Framework

7.7.3.3. Competitive Insights

7.7.3.4. Argentina ELISpot and Fluorospot Assay Market Estimates And Forecasts, 2021 - 2034 (USD Million)

7.8. MEA

7.8.1. MEA ELISpot and Fluorospot Assay Market Estimates And Forecasts, By Country, 2021 - 2034 (USD Million)

7.8.2. South Africa

7.8.2.1. Key Country Dynamics

7.8.2.2. Regulatory Framework

7.8.2.3. Competitive Insights

7.8.2.4. South Africa ELISpot and Fluorospot Assay Market Estimates And Forecasts, 2021 - 2034 (USD Million)

7.8.3. Saudi Arabia

7.8.3.1. Key Country Dynamics

7.8.3.2. Regulatory Framework

7.8.3.3. Competitive Insights

7.8.3.4. Saudi Arabia ELISpot and Fluorospot Assay Market Estimates And Forecasts, 2021 - 2034 (USD Million)

7.8.4. UAE

7.8.4.1. Key Country Dynamics

7.8.4.2. Regulatory Framework

7.8.4.3. Competitive Insights

7.8.4.4. UAE ELISpot and Fluorospot Assay Market Estimates And Forecasts, 2021 - 2034 (USD Million)

7.8.5. Kuwait

7.8.5.1. Key Country Dynamics

7.8.5.2. Regulatory Framework

7.8.5.3. Competitive Insights

7.8.5.4. Kuwait ELISpot and Fluorospot Assay Market Estimates And Forecasts, 2021 - 2034 (USD Million)

Chapter 8. Competitive Landscape

8.1. Participant Overview

8.2. Company Market Position Analysis

8.3. Company Categorization

8.4. Strategy Mapping

8.5. Company Profiles/Listing

8.5.1. BD

8.5.1.1. Overview

8.5.1.2. Financial Performance

8.5.1.3. Product Benchmarking

8.5.1.4. Strategic Initiatives

8.5.2. U-CyTech

8.5.2.1. Overview

8.5.2.2. Financial Performance

8.5.2.3. Product Benchmarking

8.5.2.4. Strategic Initiatives

8.5.3. Cellular Technology Limited

8.5.3.1. Overview

8.5.3.2. Financial Performance

8.5.3.3. Product Benchmarking

8.5.3.4. Strategic Initiatives

8.5.4. Mabtech

8.5.4.1. Overview

8.5.4.2. Financial Performance

8.5.4.3. Product Benchmarking

8.5.4.4. Strategic Initiatives

8.5.5. Abcam Limited

8.5.5.1. Overview

8.5.5.2. Financial Performance

8.5.5.3. Product Benchmarking

8.5.5.4. Strategic Initiatives

8.5.6. Autoimmun Diagnostika GmbH

8.5.6.1. Overview

8.5.6.2. Financial Performance

8.5.6.3. Product Benchmarking

8.5.6.4. Strategic Initiatives

8.5.7. Lophius Biosciences GmbH

8.5.7.1. Overview

8.5.7.2. Financial Performance

8.5.7.3. Product Benchmarking

8.5.7.4. Strategic Initiatives

8.5.8. Bio-Connect B.V.

8.5.8.1. Overview

8.5.8.2. Financial Performance

8.5.8.3. Product Benchmarking

8.5.8.4. Strategic Initiatives

8.5.9. Oxford Immunotec

8.5.9.1. Overview

8.5.9.2. Financial Performance

8.5.9.3. Product Benchmarking

8.5.9.4. Strategic Initiatives

8.5.10. Bio-Techne Corporation

8.5.10.1. Overview

8.5.10.2. Financial Performance

8.5.10.3. Product Benchmarking

8.5.10.4. Strategic Initiatives

Proceed To Buy

USD 4500
USD 3900
USD 1900
USD 1200

Customization Offered

  • check-img Cross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers